Trial Profile
A trial of natalizumab to evaluate the alterations in circulating B-cells of multiple sclerosis patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 26 Feb 2016 New trial record